286 related articles for article (PubMed ID: 28971838)
1. Hyperglucagonemia correlates with plasma levels of non-branched-chain amino acids in patients with liver disease independent of type 2 diabetes.
Wewer Albrechtsen NJ; Junker AE; Christensen M; Hædersdal S; Wibrand F; Lund AM; Galsgaard KD; Holst JJ; Knop FK; Vilsbøll T
Am J Physiol Gastrointest Liver Physiol; 2018 Jan; 314(1):G91-G96. PubMed ID: 28971838
[TBL] [Abstract][Full Text] [Related]
2. The Liver-α-Cell Axis and Type 2 Diabetes.
Wewer Albrechtsen NJ; Pedersen J; Galsgaard KD; Winther-Sørensen M; Suppli MP; Janah L; Gromada J; Vilstrup H; Knop FK; Holst JJ
Endocr Rev; 2019 Oct; 40(5):1353-1366. PubMed ID: 30920583
[TBL] [Abstract][Full Text] [Related]
3. Determinants of Fasting Hyperglucagonemia in Patients with Type 2 Diabetes and Nondiabetic Control Subjects.
Demant M; Bagger JI; Suppli MP; Lund A; Gyldenløve M; Hansen KB; Hare KJ; Christensen M; Sonne DP; Holst JJ; Vilsbøll T; Knop FK
Metab Syndr Relat Disord; 2018 Dec; 16(10):530-536. PubMed ID: 30325692
[TBL] [Abstract][Full Text] [Related]
4. Glucagon acutely regulates hepatic amino acid catabolism and the effect may be disturbed by steatosis.
Winther-Sørensen M; Galsgaard KD; Santos A; Trammell SAJ; Sulek K; Kuhre RE; Pedersen J; Andersen DB; Hassing AS; Dall M; Treebak JT; Gillum MP; Torekov SS; Windeløv JA; Hunt JE; Kjeldsen SAS; Jepsen SL; Vasilopoulou CG; Knop FK; Ørskov C; Werge MP; Bisgaard HC; Eriksen PL; Vilstrup H; Gluud LL; Holst JJ; Wewer Albrechtsen NJ
Mol Metab; 2020 Dec; 42():101080. PubMed ID: 32937194
[TBL] [Abstract][Full Text] [Related]
5. Determinants of hyperglucagonemia in pediatric non-alcoholic fatty liver disease.
Maruszczak K; Radzikowski K; Schütz S; Mangge H; Bergsten P; Forslund A; Manell H; Pixner T; Ahlström H; Kullberg J; Mörwald K; Weghuber D
Front Endocrinol (Lausanne); 2022; 13():1004128. PubMed ID: 36133310
[TBL] [Abstract][Full Text] [Related]
6. Evidence of a liver-alpha cell axis in humans: hepatic insulin resistance attenuates relationship between fasting plasma glucagon and glucagonotropic amino acids.
Wewer Albrechtsen NJ; Færch K; Jensen TM; Witte DR; Pedersen J; Mahendran Y; Jonsson AE; Galsgaard KD; Winther-Sørensen M; Torekov SS; Lauritzen T; Pedersen O; Knop FK; Hansen T; Jørgensen ME; Vistisen D; Holst JJ
Diabetologia; 2018 Mar; 61(3):671-680. PubMed ID: 29305624
[TBL] [Abstract][Full Text] [Related]
7. The liver-alpha cell axis associates with liver fat and insulin resistance: a validation study in women with non-steatotic liver fat levels.
Gar C; Haschka SJ; Kern-Matschilles S; Rauch B; Sacco V; Prehn C; Adamski J; Seissler J; Wewer Albrechtsen NJ; Holst JJ; Lechner A
Diabetologia; 2021 Mar; 64(3):512-520. PubMed ID: 33275161
[TBL] [Abstract][Full Text] [Related]
8. Non-Alcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: Role of Circulating Branched-Chain Amino Acids.
van den Berg EH; Flores-Guerrero JL; Gruppen EG; de Borst MH; Wolak-Dinsmore J; Connelly MA; Bakker SJL; Dullaart RPF
Nutrients; 2019 Mar; 11(3):. PubMed ID: 30917546
[TBL] [Abstract][Full Text] [Related]
9. Postprandial dysfunction in fatty liver disease.
Grandt J; Jensen AH; Werge MP; Rashu EB; Møller A; Junker AE; Hobolth L; Mortensen C; Johansen CD; Vyberg M; Serizawa RR; Møller S; Gluud LL; Wewer Albrechtsen NJ
Physiol Rep; 2023 Apr; 11(8):e15653. PubMed ID: 37078380
[TBL] [Abstract][Full Text] [Related]
10. Diabetes and branched-chain amino acids: What is the link?
Bloomgarden Z
J Diabetes; 2018 May; 10(5):350-352. PubMed ID: 29369529
[TBL] [Abstract][Full Text] [Related]
11. Blood Levels of the
Ghodsian N; Gagnon E; Bourgault J; Gobeil É; Manikpurage HD; Perrot N; Girard A; Mitchell PL; Arsenault BJ
Nutrients; 2021 Nov; 13(12):. PubMed ID: 34959760
[TBL] [Abstract][Full Text] [Related]
12. Glycemic Measures and Development and Resolution of Nonalcoholic Fatty Liver Disease in Nondiabetic Individuals.
Wang B; Li M; Zhao Z; Wang S; Lu J; Chen Y; Xu M; Wang W; Ning G; Bi Y; Wang T; Xu Y
J Clin Endocrinol Metab; 2020 May; 105(5):. PubMed ID: 32144419
[TBL] [Abstract][Full Text] [Related]
13. Plasma Fibroblast Growth Factor 21 Is Associated With Severity of Nonalcoholic Steatohepatitis in Patients With Obesity and Type 2 Diabetes.
Barb D; Bril F; Kalavalapalli S; Cusi K
J Clin Endocrinol Metab; 2019 Aug; 104(8):3327-3336. PubMed ID: 30848827
[TBL] [Abstract][Full Text] [Related]
14. The Liver-α-Cell Axis in Health and in Disease.
Richter MM; Galsgaard KD; Elmelund E; Knop FK; Suppli MP; Holst JJ; Winther-Sørensen M; Kjeldsen SAS; Wewer Albrechtsen NJ
Diabetes; 2022 Sep; 71(9):1852-1861. PubMed ID: 35657688
[TBL] [Abstract][Full Text] [Related]
15. Serum dipeptidyl peptidase-4 activity in insulin resistant patients with non-alcoholic fatty liver disease: a novel liver disease biomarker.
Firneisz G; Varga T; Lengyel G; Fehér J; Ghyczy D; Wichmann B; Selmeci L; Tulassay Z; Rácz K; Somogyi A
PLoS One; 2010 Aug; 5(8):e12226. PubMed ID: 20805868
[TBL] [Abstract][Full Text] [Related]
16. Higher glucagon-to-insulin ratio is associated with elevated glycated hemoglobin levels in type 2 diabetes patients.
Lee M; Kim M; Park JS; Lee S; You J; Ahn CW; Kim KR; Kang S
Korean J Intern Med; 2019 Sep; 34(5):1068-1077. PubMed ID: 28882024
[TBL] [Abstract][Full Text] [Related]
17. Insulin resistance, but not insulin response, during oral glucose tolerance test (OGTT) is associated to worse histological outcome in obese NAFLD.
Coccia F; Testa M; Guarisco G; Di Cristofano C; Silecchia G; Leonetti F; Gastaldelli A; Capoccia D
Nutr Metab Cardiovasc Dis; 2020 Jan; 30(1):106-113. PubMed ID: 31677889
[TBL] [Abstract][Full Text] [Related]
18. Fetuin-B links nonalcoholic fatty liver disease to type 2 diabetes via inducing insulin resistance: Association and path analyses.
Li Z; Lin M; Liu C; Wang D; Shi X; Chen Z; Liu Y; Yang S; Li X
Cytokine; 2018 Aug; 108():145-150. PubMed ID: 29609136
[TBL] [Abstract][Full Text] [Related]
19. Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance.
Gaggini M; Carli F; Rosso C; Buzzigoli E; Marietti M; Della Latta V; Ciociaro D; Abate ML; Gambino R; Cassader M; Bugianesi E; Gastaldelli A
Hepatology; 2018 Jan; 67(1):145-158. PubMed ID: 28802074
[TBL] [Abstract][Full Text] [Related]
20. [Incretins-adipocytokines interactions in type 2 diabetic subjects with or without non-alcoholic fatty liver disease: interest of GLP-1 (glucagon-like peptide-1) as a modulating biomarker].
Chellali S; Boudiba A; Griene L; Koceir EA
Ann Biol Clin (Paris); 2019 Jun; 77(3):261-271. PubMed ID: 30998190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
